Sandoz Receives EC Approval For Zessly As Remicade Biosimilar
NewsZessly is approved for use in all indications of the reference medicine including rheumatoid arthritis adult Crohn's disease pediatric Crohn's disease adult ulcerative colitis pediatric ulcerative...
View ArticlePhase III IMpower130 Study Showed Genentechs TECENTRIQ Atezolizumab Plus...
Genentech a member of the Roche Group SIX RO ROG; OTCQX RHHBY today announced that the Phase III IMpower130 study met its coprimary endpoints of overall survival OS and progressionfree survival PFS....
View ArticleIntestinal Paracoccidioidomycosis Resembling Crohn's Disease
In this case a fungal disease convincingly mimicked clinical manifestations and colonoscopic and histological findings of Crohn's disease. Journal of Medical Case Reports
View ArticleLabRoots Champions the Advancements in Precision Medicine With 3rd Annual...
LabRoots will host the twoday conference on June 2021 where attendees will gain a better understanding of the new developments in precision medicine and surrounding topics.PRWEB May 30 2018 LabRoots...
View ArticlePfizer Announces U.S. FDA Approves XELJANZÂ tofacitinib for the Treatment of...
XELJANZ an Oral Therapy is the First and Only JAK Inhibitor Approved in the U.S. for This Patient Population Pfizer Inc. NYSE PFE announced today that the United States U.S. Food and Drug...
View ArticleSandoz receives positive CHMP opinion for proposed biosimilar adalimumab
Novartis International AG Sandoz receives positive CHMP opinion for proposed biosimilar adalimumab. Processed and transmitted by Nasdaq Corporate Solutions.The issuer is solely responsible for the...
View ArticleHidradenitis Suppurativa Tied to Increased Risk of Crohn's Disease
Patients with hidradenitis suppurativa HS a skin disorder characterized by painful nodules and abscesses may be at increased risk for Crohn's disease CD and those with GI symptoms should be seen by a...
View ArticlePhase III IMpower131 Study Showed Genentechs TECENTRIQ Atezolizumab Plus...
Data will be featured in the ASCO press program on Saturday June 2 and presented at ASCO on Monday June 4 Genentech a member of the Roche Group SIX RO ROG; OTCQX RHHBY today announced that results from...
View ArticleNovel PET imaging noninvasively pinpoints colitis inflammation
Society of Nuclear Medicine and Molecular Imaging A novel positron emission tomography PET imaging method shows promise for noninvasively pinpointing sites of inflammation in people with inflammatory...
View ArticleJohnson & Johnsons Stelara Improves Crohns In TwoYear Study
The Janssen Pharmaceutical Companies part of Johnson & Johnson presented twoyear data from its IMUNITI trial of Stelara ustekinumab in Crohns disease.
View ArticleTakeda Highlights Favorable Safety Profile of EntyvioR vedolizumab Through...
OSAKA Japan June 4 2018 PRNewswire Takeda demonstrates leadership in GI by featuring new U.S. VICTORY Consortium data among its 24 sponsored Entyvio abstracts presented at the Digestive Disease Week...
View ArticleNovel PET imaging shows promise for noninvasively detecting inflammation in...
A novel positron emission tomography imaging method shows promise for noninvasively pinpointing sites of inflammation in people with inflammatory bowel disease which includes ulcerative colitis and...
View ArticleNimbus Therapeutics Announces $65 Million in New Financing to Accelerate...
Nimbus Therapeutics a privately held biotechnology company applying deep computational expertise throughout drug discovery and development today announced that it has raised $65 million in new capital...
View ArticleJanssen unveils new data on Crohns disease treatment
Johnson and Johnson subsidiary Janssen has presented new data at the 2018 Digestive Disease Week in Washington DC from its...Read More...The post Janssen unveils new data on Crohns disease treatment...
View ArticleJanssen unveils new data on its ustekinumab treatment for Crohns disease
Johnson and Johnson subsidiary Janssen has presented new data at the 2018 Digestive Disease Week in Washington DC from its...Read More...The post Janssen unveils new data on its ustekinumab treatment...
View ArticleLandos Biopharma Announces Human Translational Results for Mechanisms of BT11...
Landos Biopharma Inc. an emerging biopharmaceutical company focused on developing improved treatments for autoimmune diseases presented findings from mechanisms of action studies for its lead candidate...
View ArticleNew subcutaneous formulation of Celltrion Healthcares CTP13 biosimilar...
Data showed that the subcutaneous SC administration of CTP13 was comparable in terms of efficacy and safety with intravenous IV administration of CTP13 RemsimaÂInflectra As a global leader in...
View ArticleData Shows Treatment with Janssens Stelara Reduced Rates of Hospitalization...
WASHINGTON DC&8211;BUSINESS WIRE&8211;The Janssen Pharmaceutical Companies of Johnson &38; Johnson announced today a new analysis looking at twoyear data from the IMUNITI longterm extension...
View ArticleVitality Biopharma CEO says cannabinoids have potential for...
Vitality Biopharma OTCQBVBIO CEO Robert Brooke tells Proactive Investors about the company's development of cannabinoid prodrug pharmaceuticals and how cannabinoids can be used for the treatment of...
View Article